ARTHRITIS & RHEUMATISM Vol. 62, No. 1, January 2010, pp 22–32 DOI 10.1002/art.27227 © 2010, American College of Rheumatology Direct Comparison of Treatment Responses, Remission Rates, and Drug Adherence in Patients With Rheumatoid Arthritis Treated With Adalimumab, Etanercept, or Infliximab Results From Eight Years of Surveillance of Clinical Practice in the Nationwide Danish DANBIO Registry Merete Lund Hetland, 1 Ib Jarle Christensen, 2 Ulrik Tarp, 3 Lene Dreyer, 4 Annette Hansen, 5 Ib Tønder Hansen, 6 Gina Kollerup, 7 Louise Linde, 1 Hanne M. Lindegaard, 8 Uta Engling Poulsen, 9 Annette Schlemmer, 10 Dorte Vendelbo Jensen, 11 Signe Jensen, 12 Gisela Hostenkamp, 13 and Mikkel Østergaard, 14 on Behalf of All Departments of Rheumatology in Denmark Objective. To compare tumor necrosis factor  inhibitors directly regarding the rates of treatment response, remission, and the drug survival rate in patients with rheumatoid arthritis (RA), and to identify clinical prognostic factors for response. Methods. The nationwide DANBIO registry col- lects data on rheumatology patients receiving routine care. For the present study, we included patients from DANBIO who had RA (n  2,326) in whom the first biologic treatment was initiated (29% received adali- mumab, 22% received etanercept, and 49% received infliximab). Baseline predictors of treatment response were identified. The odds ratios (ORs) for clinical responses and remission and hazard ratios (HRs) for drug withdrawal were calculated, corrected for age, disease duration, the Disease Activity Score in 28 joints Supported by unrestricted grants to DANBIO from Abbott, Wyeth, and Schering-Plough (since 2004), Bristol-Myers Squibb, and Roche (since 2006), and UCB-Nordic (since 2007). The Danish Regions provided financial support for the activities related to quality improvement of biologic treatment. Dr. Hetland’s work was supported by a grant from the Danish Rheumatism Association and by the Margarethe Astrid Hedvig Schaufuss Legat. 1 Merete Lund Hetland, MD, PhD, Louise Linde, MD: DAN- BIO Registry, and Copenhagen University Hospital, Hvidovre and Glostrup, Denmark; 2 Ib Jarle Christensen, MSc: The Finsen Labora- tory, Copenhagen University Hospital, Rigshospitalet, Denmark; 3 Ul- rik Tarp, MD, DMSc: Aarhus University Hospital, Aarhus, Denmark; 4 Lene Dreyer, MD, PhD: Copenhagen University Hospital, Rigshos- pitalet, Denmark; 5 Annette Hansen, MD: DANBIO Registry, and Copenhagen University Hospital, Gentofte, Denmark; 6 Ib Tønder Hansen, MD, PhD: Viborg Hospital, Viborg, Denmark; 7 Gina Kollerup, MD, PhD: Copenhagen University Hospital, Bispebjerg, Denmark; 8 Hanne M. Lindegaard, MD, PhD: Odense University Hospital, Odense, Denmark; 9 Uta Engling Poulsen, MD: Rheumatism Hospital, University of Southern Denmark, Graasten, Denmark; 10 An- nette Schlemmer, MD, Aarhus University Hospital, Aalborg, Den- mark; 11 Dorte Vendelbo Jensen, MD: Hørsholm Hospital, Hørsholm, Denmark; 12 Signe Jensen, MD: Copenhagen University Hospital, Gentofte, Denmark; 13 Gisela Hostenkamp, MSc: Institute for Public Health, Health Economic Unit, Odense, Denmark; 14 Mikkel Øster- gaard, MD, PhD, DMSc: Copenhagen University Hospital, Hvidovre and Glostrup, and Copenhagen University Hospital, Gentofte, Den- mark. Dr. Hetland has received consulting fees, speaking fees, and/or research grants from Abbott, Centocor, Roche, Schering- Plough, UCB-Nordic, and Wyeth (less than $10,000 each), and, on behalf of DANBIO, she has received grants from Abbott, Bristol- Myers Squibb, Roche, Schering-Plough, UCB-Nordic, and Wyeth (more than $10,000 each). Dr. Tarp has received consulting and/or speaking fees from Abbott, Genmab, Roche, Schering-Plough, and Wyeth (less than $10,000 each). Dr. A. Hansen has received consulting fees, speaking fees, and/or research grants from Abbott and Schering- Plough (less than $10,000 each). Dr. Kollerup has received consulting fees from Abbott (less than $10,000). Dr. Linde has received a study grant from Schering-Plough (more than $10,000). Dr. Lindegaard has received consulting fees from Abbott, Roche, and Bristol-Myers Squibb (less than $10,000 each). Dr. Schlemmer has received speaking fees from Schering-Plough (less than $10,000). Dr. D. V. Jensen has received speaking fees from Wyeth (less than $10,000). Dr. Østergaard has received consulting fees, speaking fees, and/or research grants from Abbott, Amgen, Bristol-Myers Squibb, Centocor, Genmab, Gl- axoSmithKline, Novo, Pfizer, Roche, Schering-Plough, UCB, and Wyeth (less than $10,000 each). Address correspondence and reprint requests to Merete Lund Hetland, MD, PhD, DANBIO, Copenhagen University Hospital at Hvidovre, Department of Rheumatology 232, Kettegård Alle 30, DK 2650 Hvidovre, Denmark. E-mail: merete.hetland@dadlnet.dk. Submitted for publication May 27, 2009; accepted in revised form September 16, 2009. 22